May 14th, 2014
Informed Interpretation of the 20-Year Results of the DIGAMI Trial
Valentin Fuster, MD
Darren McGuire gives us his perspective on the DIGAMI trial results.
NEJM — Recent Cardiology Articles- Intention to Treat — Season 2: The Race Equation: BiDil — The Story of the Black Pill — ITT Episode 2.5 June 4, 2026How did a drug for congestive heart failure get approved and marketed for Black people only?
- Left Atrial Appendage Closure — Should Recommendations Be Expanded? June 4, 2026Owing to the fact that most thromboembolic complications that are attributed to atrial fibrillation originate in the left atrial appendage,1 therapies targeting the anatomical structure that might spare systemic harms are theoretically attractive. Randomized trials of left atrial appendage closure previously garnered an American College of Cardiology–American Heart...
- Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation June 4, 2026In patients with atrial fibrillation, left atrial appendage closure was noninferior to NOACs in an analysis of death from cardiovascular causes, stroke, or systemic embolism and was superior for non–procedure-related bleeding.
- Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting June 3, 2026Since Dr. Phillip Hench reported on the efficacy of glucocorticoids for rheumatoid arthritis in 1949, glucocorticoids have saved many lives and have offered relief to countless patients. Glucocorticoids have been used as the mainstay of treatment for many immune-mediated inflammatory diseases, including polymyalgia rheumatica and giant-cell arteritis (GCA), owing to...
- Science behind the Study: Remuscularizing the Failing Human Heart May 28, 2026The author describes the scientific foundations of a phase 1–2 study of stem-cell–derived ventricular assist tissue transplanted onto the epicardial surface of failing human hearts.
- Intention to Treat — Season 2: The Race Equation: BiDil — The Story of the Black Pill — ITT Episode 2.5 June 4, 2026